OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy

Antibodies targeting checkpoint inhibitors or co‐stimulatory receptors on T cells have shown significant antitumor efficacy in preclinical and clinical studies. In mouse tumor models, engagement of activating Fcγ receptor (FcγR)‐expressing immune cells was recently shown to be required for the tumor...

Ausführliche Beschreibung